Sustainable Global Health Systems and Pharmaceutical Development (Aaps Advances in the Pharmaceutical Sciences Series) (2024)

個数:

Sustainable Global Health Systems and Pharmaceutical Development (Aaps Advances in the Pharmaceutical Sciences Series) (2024)

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 247 p.
  • 言語 ENG
  • 商品コード 9783031504143

Full Description

Strategic decision-making focusing on economics is the fundamental requirement to generate efficiency and improve productivity in any manufacturing environment.  In the 21st century, the science of drug development is an established field that requires a dedicated and synergistic partnership between various subject matter experts.  Unfortunately, pharmaceutical research is complicated, time-consuming, attritive, and costly, with development costs ranging from $4 billion to $11 billion per commercialized drug.  There are more than 750 biotech and big pharma companies in the US that are developing new drug products for a vast number of therapeutic indications.  Due to the high attrition rate in clinical trials, a small percentage of these drugs get commercialized.  Still, a very high amount of resources are being spent on drug development from a societal perspective.

 

Despite being an economically intense activity, the current state of drug product development makes a limited effort to integrate economics into product design and development.  For example, pharmaceutical scientists are excellent at a data-driven decision-making process that requires technical elements and a few strategic elements.  However, there is minimal integration of financial valuation elements (commonly employed in other high-tech industries such as fine chemicals, automotive, aerospace, etc.) into pharmaceutical drug development.  Unfortunately, this hurts the sustainability of the health system of which these products will be a part in the future. 

 

A desirable future state integrates fundamentals of economics in product design and development so that the decision-making is parameterized, the cost of goods can be lowered, wastage can be reduced, patient-centricity is built into the design, and manufacturing/distribution efficiencies can be gained.  The financial benefits of such an approach could allow for these savings to be passed on to the stakeholders and improve the value proposition of pharmaceuticals, which is critical to maintaining the innovation potential.  This book hopes to introduce the reader to this desired future state of pharmaceutical drug development.

 

Contents

Health Care Industry.-​ Reimbursement and Pricing​.- Current Stage of Pharmaceutical Development​.- Desired Future State of Pharmaceutical Development​.- Case Studies I​.- Case Studies II​.- Case Studies III.

最近チェックした商品